Visible Genetics, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Private placement of 1.9 mil. shares with U.S. and European institutional investors raises $28.7 mil. A portion of the funds will be used to gear up U.S. marketing and manufacturing efforts for the TruGene HIV-I genotyping kit, an FDA regulatory submission for which is anticipated in the first half of 2000 (1"The Gray Sheet" Dec. 6, p. 14). The proceeds will be directed toward new product development and for general working capital, the Toronto firm says
You may also be interested in...
Visible Genetics Preparing TruGene HIV Genotyping Assay FDA Submission
Visible Genetics, Inc. is looking to file an FDA application for its TruGene HIV genotyping assay kit in the first half of 2000, the company reported Nov. 30 at a BancBoston Robertson Stephens health care conference in New York City.
Cosmetic And Personal Care Trademark Review 24 November, 2020
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
CBD Health Benefits More Attractive To Women? FDA Prioritizes Research Into Utero Effects
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: